Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

11q deletions in hematological malignancies.

O Monni1, S Knuutila

  • 1Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda 20892, MD, USA.

Leukemia & Lymphoma
|June 28, 2001
PubMed
Summary

Structural aberrations in 11q, particularly deletions at 11q23, are common in hematological malignancies. The ATM gene is implicated in tumorigenesis, suggesting its dysfunction contributes to these cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Narcolepsy patients' blood-based miRNA expression profiling: miRNA expression differences with Pandemrix vaccination.

Acta neurologica Scandinavica·2017
Same author

Cytogenetic Findings and Survival in B-cell Chronic Lymphocytic Leukemia. Second IWCCLL Compilation of Data on 662 Patients.

Leukemia & lymphoma·2016
Same author

t(2;5) (p23;q35)-A Specific Chromosome Abnormality in Large Cell Anaplastic (Ki-1) Lymphoma.

Leukemia & lymphoma·2016
Same author

Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers.

Oncogene·2015
Same author

MicroRNA profiling in chemoresistant and chemosensitive acute myeloid leukemia.

Cytogenetic and genome research·2013
Same author

Integrated analysis of gene copy number, copy neutral LOH, and microRNA profiles in adult acute lymphoblastic leukemia.

Cytogenetic and genome research·2012

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Structural aberrations involving the 11q chromosome region are frequently observed in hematological malignancies.
  • Breakpoints at 11q23 suggest the presence of a crucial tumor suppressor gene involved in lymphoproliferative disorders.
  • 11q deletions are notably prevalent in specific subtypes like B-cell chronic lymphocytic leukemia (B-CLL), mantle cell lymphoma (MCL), and T-cell prolymphocytic leukemia (T-PLL).

Purpose of the Study:

  • To investigate the significance of 11q deletions and ATM gene dysfunction in the development of hematological malignancies.
  • To explore the role of the ATM gene as a potential tumor suppressor in B-CLL, MCL, and T-PLL.
  • To evaluate the diagnostic utility of 11q deletions in specific hematological cancers.

Main Methods:

  • Analysis of structural aberrations, including translocations and deletions, in various hematological malignancies.
  • Fluorescence in situ hybridization (FISH) to detect deletions at 11q23.
  • Mutation analysis of the ATM gene in patients with 11q deletions.

Main Results:

  • 11q deletions are found in 20-30% of B-CLL cases and nearly 50% of MCL cases.
  • 11q deletion in B-CLL is linked to faster disease progression and poorer survival in younger patients.
  • Mutations in the ATM gene were identified in B-CLL, MCL, and T-PLL cases with 11q deletions.

Conclusions:

  • 11q deletions and ATM gene dysfunction are significant in the tumorigenesis of certain hematological malignancies.
  • The ATM gene is a likely tumor suppressor targeted by 11q deletions.
  • Further research is needed to validate 11q deletion as a diagnostic marker and identify other potential target genes within the deleted region.

Related Experiment Videos